Author Year Study type Sample size Antiplatelets used Measurements Conclusion
Bednar et al 2009 Prospective cohort 40 Aspirin Platelet aggregation, 11-dehydro thromboxane B2 Aspirin does not inhibit platelet aggregation sufficiently in early postoperative days.
Bednar et al 2012 Prospective cohort 30 Aspirin + Clopidogrel Platelet aggregation, 11-dehydro thromboxane B2 Aspirin-induced inhibition of thromboxane B2 production and platelet aggregation is impaired in the early days of the postoperative period.
Bollinger et al 2016 Prospective cohort 304 Aspirin Platelet aggregation Reduced aspirin responsiveness is not associated with major adverse events after CABG.
Brambilla et al 2010 Randomised controlled trial 56 Aspirin Platelet aggregation, 11-dehydro thromboxane B2 Incidence of antiplatelet resistance is lower with a higher dosage of aspirin.
Gasparovic et al 2014 Randomised controlled trial 219 Aspirin Platelet aggregation Addition of clopidogrel to aspirin-resistant patients does not reduce adverse outcomes nor increase bleeding.
Hiyasat et al 2014 Prospective cohort 100 Aspirin Platelet aggregation Aspirin resistance occurs in a large population of patients after CABG and is associated with worse outcomes.
Kempfert et al 2009 Prospective cohort 59 Aspirin Platelet aggregation Aspirin resistance is a transient phenomenon in a large population of patients undergoing CABG.
Mannacio et al 2012 Randomised controlled trial 300 Aspirin Platelet function assay Aspirin resistance is a predictor of vein graft patency, and dual antiplatelet therapy improves it.
Nicola et al 2019 Prospective cohort 250 Aspirin Platelet aggregation Aspirin effects slightly increase blood loss and the requirement of allogeneic blood transfusion.
Petricevic et al 2013 Prospective cohort 131 Aspirin + Clopidogrel Platelet aggregation Dose adjustment or dual antiplatelet therapy should be considered in aspirin-resistant patients to reduce adverse events.
Petricevic et al 2011 Prospective cohort 99 Aspirin Platelet aggregation Postoperative aspirin administration does not sufficiently inhibit platelet aggregation in CABG patients.
Poston et al 2006 Prospective cohort 225 Aspirin Platelet aggregation, 11-dehydro thromboxane B2, whole blood flow cytometry Aspirin resistance and compromised endothelial integrity lead to vein graft failure within a few days after off-pump CABG surgery.
Wand et al 2017 Prospective cohort 400 Aspirin Platelet aggregation High incidence of perioperative aspirin non-response rate does not increase 1-year cardiovascular adverse event rate.
Wang et al 2012 Prospective cohort 333 Aspirin + Clopidogrel Platelet aggregation, 11-dehydro thromboxane B2 Aspirin resistance is a transient phenomenon in the early postoperative period.
Yilmaz et al 2005 Prospective cohort 28 Aspirin Platelet function assay Aspirin resistance is highly prevalent in patients with late occlusion of vein grafts.
Youn et al 2014 Prospective cohort 859 Aspirin + Clopidogrel Platelet function assay High residual platelet activity after clopidogrel administration is associated with a higher 1-year adverse event rate.
Willemsen et al 2021 Prospective cohort 128 Aspirin Platelet function assay Aspirin-sensitive patients have more 12-hour blood loss after CABG.
Zimmermann et al 2005 Prospective cohort 29 Aspirin Platelet aggregation The antiplatelet effect of aspirin is largely impaired after on-pump, but not off-pump CABG.